Bifeprunox
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Bifeprunox (
serotonin receptor agonism.[1] It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.[2]
In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."[5]
Pharmacodynamics
Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.
See also
References
- PMID 17300168.
- ^ "Bifeprunox". go.drugbank.com. Retrieved 2023-11-16.
- S2CID 23291727.
- ^ Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox. Thomson Financial, August 10, 2007.
- ^ Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued Archived 2011-07-14 at the Wayback Machine Lundbeck Press Release.